Ching-Yao Yang1, Mong-Wei Lin2, Yih-Leong Chang3, Chen-Tu Wu4, Pan-Chyr Yang1. 1. Department of Internal Medicine, Taiwan, ROC; Graduate Institute of Pathology, National Taiwan University College of Medicine, Taipei 10002, Taiwan, ROC. 2. Department of Surgery, Taiwan, ROC; Graduate Institute of Pathology, National Taiwan University College of Medicine, Taipei 10002, Taiwan, ROC. 3. Department of Pathology, National Taiwan University Hospital and National Taiwan University College of Medicine, 7, Chung-Shan South Road, Taipei 10002, Taiwan, ROC; Graduate Institute of Pathology, National Taiwan University College of Medicine, Taipei 10002, Taiwan, ROC. Electronic address: ntuhylc@gmail.com. 4. Department of Pathology, National Taiwan University Hospital and National Taiwan University College of Medicine, 7, Chung-Shan South Road, Taipei 10002, Taiwan, ROC; Graduate Institute of Pathology, National Taiwan University College of Medicine, Taipei 10002, Taiwan, ROC.
Abstract
BACKGROUND: Programmed cell death-ligand 1 (PD-L1) is expressed in a subgroup of lung cancer that may benefit from immunotherapy. The interaction between PD-L1 expression and tumour infiltrating lymphocytes (TIL) remains poorly understood. This study investigated the expression of PD-L1 in surgically resected stage I pulmonary squamous cell carcinoma (SqCC) and correlated it with TILs in tumour microenvironments, common driver mutations, and clinical outcomes. MATERIALS AND METHODS: One hundred and five patients with surgically resected stage I squamous cell carcinoma were examined. Paraffin-embedded tumour sections were stained with PD-L1 antibody. Tumours with moderate-to-strong membrane staining in ≥ 5% of tumour cells were scored as positive for PD-L1 expression. The driver mutation epidermal growth factor receptor (EGFR), Kirsten rat sarcoma viral oncogene homolog (KRAS), and v-raf murine sarcoma viral oncogene homolog B (BRAF) were examined by direct sequencing, while anaplastic lymphoma kinase (ALK), phosphoinositide 3-kinase catalytic alpha (PI3KCA), and fibroblast growth factor receptor 1 (FGFR1) were analysed by immunohistochemistry. The correlations of PD-L1 expression with each subtype of TIL, driver mutations, clinicopathologic parameters, and clinical outcomes were analysed. RESULTS: There was positive PD-L1 expression in 56.2% (59/105) of patients. PD-L1 expression was not associated with the common clinicopathologic features and mutations of EGFR, KRAS, BRAF, ALK, PI3KCA, and FGFR1. As regards TILs composition, tumour PD-L1 expression was significantly associated with increased tumour epithelial CD8+ T cells and stromal CD4+ T cells. Otherwise, PD-L1 (+) tumour cells were negatively correlated with PD-L1 (+) immune cells within tumour stroma. By multivariate analysis, tumour PD-L1 expression and increased CD4+ T cell infiltrations in the tumour stroma were independent predictors of better overall survival and had a trend of better disease-free survival. CONCLUSIONS: PD-L1 expression is associated with a favourable immune microenvironment in stage I pulmonary SqCC and correlates with better clinical outcome.
BACKGROUND:Programmed cell death-ligand 1 (PD-L1) is expressed in a subgroup of lung cancer that may benefit from immunotherapy. The interaction between PD-L1 expression and tumour infiltrating lymphocytes (TIL) remains poorly understood. This study investigated the expression of PD-L1 in surgically resected stage I pulmonary squamous cell carcinoma (SqCC) and correlated it with TILs in tumour microenvironments, common driver mutations, and clinical outcomes. MATERIALS AND METHODS: One hundred and five patients with surgically resected stage I squamous cell carcinoma were examined. Paraffin-embedded tumour sections were stained with PD-L1 antibody. Tumours with moderate-to-strong membrane staining in ≥ 5% of tumour cells were scored as positive for PD-L1 expression. The driver mutation epidermal growth factor receptor (EGFR), Kirsten ratsarcoma viral oncogene homolog (KRAS), and v-raf murine sarcoma viral oncogene homolog B (BRAF) were examined by direct sequencing, while anaplastic lymphoma kinase (ALK), phosphoinositide 3-kinase catalytic alpha (PI3KCA), and fibroblast growth factor receptor 1 (FGFR1) were analysed by immunohistochemistry. The correlations of PD-L1 expression with each subtype of TIL, driver mutations, clinicopathologic parameters, and clinical outcomes were analysed. RESULTS: There was positive PD-L1 expression in 56.2% (59/105) of patients. PD-L1 expression was not associated with the common clinicopathologic features and mutations of EGFR, KRAS, BRAF, ALK, PI3KCA, and FGFR1. As regards TILs composition, tumour PD-L1 expression was significantly associated with increased tumour epithelial CD8+ T cells and stromal CD4+ T cells. Otherwise, PD-L1 (+) tumour cells were negatively correlated with PD-L1 (+) immune cells within tumour stroma. By multivariate analysis, tumour PD-L1 expression and increased CD4+ T cell infiltrations in the tumour stroma were independent predictors of better overall survival and had a trend of better disease-free survival. CONCLUSIONS:PD-L1 expression is associated with a favourable immune microenvironment in stage I pulmonary SqCC and correlates with better clinical outcome.
Authors: Soo Jung Lee; Sun-Young Jun; In Hee Lee; Byung Woog Kang; Su Yeon Park; Hye Jin Kim; Jun Seok Park; Gyu-Seog Choi; Ghilsuk Yoon; Jong Gwang Kim Journal: J Cancer Res Clin Oncol Date: 2018-03-08 Impact factor: 4.553
Authors: Lívia Rojkó; Lilla Reiniger; Vanda Téglási; Katalin Fábián; Orsolya Pipek; Attila Vágvölgyi; László Agócs; János Fillinger; Zita Kajdácsi; József Tímár; Balázs Döme; Zoltán Szállási; Judit Moldvay Journal: J Cancer Res Clin Oncol Date: 2018-04-19 Impact factor: 4.553
Authors: Marius Ilie; Alexander T Falk; Catherine Butori; Emmanuel Chamorey; Christelle Bonnetaud; Elodie Long; Sandra Lassalle; Katia Zahaf; Nicolas Vénissac; Jérôme Mouroux; Charlotte Cohen; Elisabeth Brambilla; Charles Hugo Marquette; Véronique Hofman; Paul Hofman Journal: Mod Pathol Date: 2016-08-26 Impact factor: 7.842
Authors: Vanda Téglási; Lilla Reiniger; Katalin Fábián; Orsolya Pipek; Irén Csala; Attila G Bagó; Péter Várallyai; Laura Vízkeleti; Lívia Rojkó; József Tímár; Balázs Döme; Zoltán Szállási; Charles Swanton; Judit Moldvay Journal: Neuro Oncol Date: 2017-08-01 Impact factor: 12.300